ArticleJournal of the Society for Cardiovascular Angiography & Interventions2026
Treating Women With Calcified Coronary Arteries Using Intravascular Lithotripsy: Primary Results of the EMPOWER CAD Study.
Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05755711 (Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease
Who cites it
1 citing paper in PubMed.
- Breaking Down Barriers … and Calcium: The EMPOWERment of Women With Calcific Coronary Artery Disease.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Percutaneous coronary intervention of severely calcified coronary lesions is associated with a higher risk of adverse events in women compared with men. Methods: EMPOWER CAD (NCT05755711) is a prospective, multicenter, single-arm "real-world" study of women receiving intravascular lithotripsy (IVL) to treat calcific coronary artery lesions. The 30-day primary safety end point was target lesion failure (TLF), a composite of cardiac death, myocardial infarction (MI), or ischemia-driven target lesion revascularization. Procedural success was defined as successful stent delivery with residual stenosis ≤30% without in-hospital TLF. Results: A total of 399 women were enrolled at 45 centers in Europe and the United States. Mean age was 73 ± 10 years; diabetes (46.1%), prior MI (32.3%), chronic kidney disease (27.8%), and prior percutaneous coronary intervention (38.8%) were prevalent. Of the patients, 23.3% presented with NSTE-ACS, 16.0% with LVEF ≤40%, 7.3% of target lesions were in the left main artery, and severe calcification was present in 99.3%. IVL was the first calcium-modifying treatment for 90.6% of lesions. Procedural success (87.4%) and TLF at 30 days (11.6%) were both driven by the 9.6% periprocedural MI rate per the Society for Cardiovascular Angiography & Interventions (SCAI) definition. Diameter stenosis was reduced from 78% ± 12% at baseline to 46% ± 12% after IVL, and to 12% ± 7% in-stent at final angiography. Seattle Angina Questionnaire (SAQ)-7, European Quality of Life 5 Dimension 5 Level (EQ-5D-5L), and GAD-7 quality-of-life measures all showed significant improvements at 30 days ( Conclusions: In the real-world EMPOWER CAD study, an IVL-first strategy demonstrated a favorable safety profile, high procedural success, and significant stenosis reduction and quality of life improvement at 30 days, consistent with or better than prior IVL studies performed in predominantly male populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.